For first time, a vaccine helps prevent HIV
Risk of infection cut by 31 percent in Thai trial of 16,000 volunteers
Video |
Study results yield new hope for HIV vaccine Sept. 24: While the positive results of an drug experiment in Thailand have surprised skeptics and experts alike, years of research are still needed to develop a vaccine that would protect more people. NBC's Robert Bazell reports. Nightly News |
Video |
msnbc.com |
Video |
Circumcision for all boys? Aug. 24: The CDC is expected to recommend that all babies in the U.S. be circumcised in order to reduce the spread of HIV. NBC’s Dr. Nancy Snyderman discusses the controversial issue. Dr. Nancy |
INTERACTIVE |
Most popular |
| |||||
BANGKOK - For the first time, an experimental vaccine has prevented infection with the AIDS virus, a watershed event in the deadly epidemic and a surprising result. Recent failures led many scientists to think such a vaccine might never be possible.
The World Health Organization and the U.N. agency UNAIDS said the results “instilled new hope” in the field of HIV vaccine research, although researchers say it likely is many years before a vaccine might be available.
The vaccine — a combination of two previously unsuccessful vaccines — cut the risk of becoming infected with HIV by more than 31 percent in the world’s largest AIDS vaccine trial of more than 16,000 volunteers in Thailand, researchers announced Thursday in Bangkok.
Even though the benefit is modest, “it’s the first evidence that we could have a safe and effective preventive vaccine,” Col. Jerome Kim told The Associated Press. He helped lead the study for the U.S. Army, which sponsored it with the National Institute of Allergy and Infectious Diseases.
The institute’s director, Dr. Anthony Fauci, warned that this is “not the end of the road,” but he said he was surprised and very pleased by the outcome.
“It gives me cautious optimism about the possibility of improving this result” and developing a more effective AIDS vaccine, Fauci said. “This is something that we can do.”
The Thailand Ministry of Public Health conducted the study. The U.S. Army has long worked with that government and others to develop and test vaccines and medicines to protect troops and the general public.
|
‘Historic milestone’
Even a marginally helpful vaccine could have a big impact. Every day, 7,500 people worldwide are newly infected with HIV; 2 million died of AIDS in 2007, UNAIDS estimates.
“Today marks a historic milestone,” said Mitchell Warren, executive director of the AIDS Vaccine Advocacy Coalition, an international group that has worked toward developing a vaccine. Warren was not involved in the study.
“It will take time and resources to fully analyze and understand the data, but there is little doubt that this finding will energize and redirect the AIDS vaccine field,” he said in a statement.
The study tested the two-vaccine combination in a “prime-boost” approach, in which the first one primes the immune system to attack HIV and the second one strengthens the response.
They are ALVAC, from Sanofi Pasteur, the vaccine division of French drugmaker Sanofi-Aventis; and AIDSVAX, originally developed by VaxGen Inc. and now held by Global Solutions for Infectious Diseases, a nonprofit founded by some former VaxGen employees.
ALVAC uses canarypox, a bird virus altered so it can’t cause human disease, to ferry synthetic versions of three HIV genes into the body. AIDSVAX contains a genetically engineered version of a protein on HIV’s surface. The vaccines are not made from whole virus — dead or alive — and cannot cause HIV.
Neither vaccine in the study prevented HIV infection when tested individually in earlier trials, and dozens of scientists had called the new one futile when it began in 2003.
“I really didn’t have high hopes at all that we would see a positive result,” Fauci confessed.
- Discuss Story On Newsvine
-
Rate Story:
View popularLowHigh - Instant Message
MORE FROM AIDS |
| Add AIDS headlines to your news reader: |
Resource guide






